Could a Regulatory Shift Spark Tilray’s Comeback Story?

Tilray shares are experiencing a remarkable surge, driven by growing investor anticipation that U.S. cannabis policy may be headed for a historic change. Market participants are betting that marijuana could soon be reclassified from its current Schedule I status to the less restrictive Schedule III under federal law. This potential shift has ignited a powerful wave of speculation around cannabis equities, but what would such a move actually mean for Tilray’s operational reality?

Financial Transformation Through Tax Reform

At the heart of this optimism lies Section 280E of the U.S. tax code, a provision that has severely hampered the profitability of cannabis businesses. This regulation currently prevents these companies from deducting standard business expenses from their taxable income. A rescheduling to Schedule III would effectively remove this burden, dramatically lowering tax liabilities across the industry.

For Tilray, this change would represent nothing short of a financial revolution. The company would suddenly gain the ability to write off expenses for staffing, marketing campaigns, and facility costs—just like any conventional business. Such a development could significantly expand profit margins and improve cash flow generation.

Should investors sell immediately? Or is it worth buying Tilray?

Spectacular Gains Amid Historical Challenges

The market has already responded vigorously to these possibilities. Tilray’s stock price has advanced an astonishing 290% over just three months, breaking through several important technical resistance levels in the process. Despite this impressive near-term performance, the longer-term chart reveals the brutal reality of the cannabis sector’s journey: shares remain approximately 99.6% below their all-time peak.

Building a Foundation for Recovery

Beyond the regulatory speculation, Tilray has been methodically strengthening its financial position. The company maintains a solid cash reserve exceeding $256 million while simultaneously reducing its debt load by approximately $100 million. In a notable achievement for fiscal 2025, Tilray reported a surprising profit of $0.02 per share, even while recording a substantial GAAP loss of $2.18 billion.

Adding to the positive sentiment, CEO Irwin Simon demonstrated his confidence in July by personally acquiring 165,000 shares. This move sends a clear signal that leadership believes in the company’s turnaround potential. While the cannabis revolution remains uncertain, market participants have clearly positioned their bets on this transformative possibility.